Literature DB >> 12707369

Cryptic CTL epitope on a murine sarcoma Meth A generated by exon extension as a novel mechanism.

Akiko Uenaka1, Yoshiki Hirano, Hidenori Hata, Sanda Win, Toshiki Aji, Motoyuki Tanaka, Toshiro Ono, Jonathan C A Skipper, Kenji Shimizu, Eiichi Nakayama.   

Abstract

Using the recently developed ELISPOT cloning methodology, we obtained cDNA clone S35 coding for the Ag epitope recognized by a murine sarcoma Meth A-specific CTL clone AT-1. Analysis of truncated S35 constructs and overlapping peptides revealed that the peptide epitope was LGAEAIFRL. AT-1 CTL lysed peptide-pulsed CMS8 cells at a nanomolar concentration, and the peptide strongly stimulated IFN-gamma production in AT-1 CTL. Sequence homology indicated that the S35 was derived from a mouse homologue of human retinoic acid-regulated nuclear matrix-associated protein (ramp). The ramp gene consisted of 15 exons. The majority of the ramp mRNA was the transcript normally spliced between exons 14 and 15, but a minor population of mRNA with an extended exon 14 was also present in Meth A cells. The epitope was derived from the newly created open reading frame, which resulted from extension of exon 14 after splicing of the adjacent intronic sequence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707369     DOI: 10.4049/jimmunol.170.9.4862

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Alternative translational reading frames as a novel source of epitopes for an expanded CD8 T-cell repertoire: use of a retroviral system to assess the translational requirements for CTL recognition and lysis.

Authors:  Timothy L Carlson; Kathy A Green; William R Green
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

Review 2.  Alternative tumour-specific antigens.

Authors:  Christof C Smith; Sara R Selitsky; Shengjie Chai; Paul M Armistead; Benjamin G Vincent; Jonathan S Serody
Journal:  Nat Rev Cancer       Date:  2019-07-05       Impact factor: 60.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.